The efficiency of PARP inhibitors was first related to pathogenic alterations in BRCA1 and BRCA2, but homologous recombination deficiency (HRD) has since been proven to sensitize ovarian tumors to PARP inhibitors as well [28,30]. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.